Global Health Limited’s Board of Directors has greenlit the unaudited standalone and consolidated financial results for Q3 2026 and the nine months ending December 31, 2025. They have also appointed Malik Mohd. Ashhab as Head-Diagnostic Services and recommended the reappointment of Independent Directors Dr. Ravi Gupta and Rajan Bharti Mittal, along with the appointment of Ms. Shonan Purie Trehan as Non-Executive Non-Independent Director, subject to shareholder approval.
Financial Results Approved
The Board of Directors at Global Health Limited has approved the unaudited standalone and consolidated financial results for the third quarter (Q3) of fiscal year 2026, alongside the results for the nine-month period ending December 31, 2025. A summary of consolidated results are:
Key Financial Figures
The total income for Q3 2026 reached ₹11,428.29 million, compared to ₹9,594.60 million in Q3 2025. Total expenses stood at ₹9,864.48 million, yielding a profit before tax of ₹1,197.83 million. Profit after tax was ₹950.33 million.
For the nine months ending December 31, 2025, the company reported total income of ₹33,130.71 million and total expenses of ₹27,843.12 million, resulting in a profit before tax of ₹5,277.38 million and a profit after tax of ₹4,124.15 million.
Leadership Appointments
Malik Mohd. Ashhab has been appointed as the ‘Head-Diagnostic Services’ effective February 4, 2026. The Board has also recommended the reappointment of existing Independent Directors, as well as the appointment of a new Non-Executive Director, all subject to shareholder approval. These include:
- Re-appointment of Dr. Ravi Gupta as an Independent Director for a second term of five years starting July 8, 2026.
- Re-appointment of Mr. Rajan Bharti Mittal as an Independent Director for a second term of five years starting July 8, 2026.
- Appointment of Ms. Shonan Purie Trehan as a Non-Executive Non-Independent Director, liable to retire by rotation, effective March 13, 2026.
Source: BSE
